This contract includes preclinical and manufacturing development activities including cell line development; process development; non-clinical efficacy studies; non-clinical safety studies;…

Active Definitive Contract Awarded Last action

Contract number
75A50119C00054
Awardee
Awarding agency
Obligated
$65,806,222

Award facts

Contract value 100% obligated
$65,806,222.33 Current and potential, with all options
Completion date 75% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21701, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00018 -$428
Terminate for Convenience P00017 · EOI::presidential cost savings initiative (february 26, 2025)::EOI notice of termination for convenience $0
Exercise an Option P00016 · The purpose of this bilateral modification is to accomplish all of the following objectives: 1. MOD CLIN0003 to fund COA request 10.3, to cover the care and… $7,786,260
Other Administrative Action P00015 · The purpose of this bilateral modification is to 1. Extend the period of performance for the base period at no cost to the government. As a result of this… $0
Exercise an Option P00014 · The purposes of this modification are to 1. Add funding to option 2 (clin 0003) in the amount of $230,896.03. 2. Exercise option 4 (clin 0005) in the amount… $16,243,348
Funding Only Action P00013 · Add funding to option 2 (clin 0003) in the amount of $928,249.32. This includes $269,855.08 to account for G & a and fee as well as $658,394.25 for additional… $928,249
Funding Only Action P00012 · Modification 12 adds funding in the amount of $1,707,218.18 to clin 0003 option period 2 $1,707,218
Change Order P00011 · Modification 11 extends the POP of base period to end on october 20, 2023 at no extra cost to the government. $0
Exercise an Option P00010 · Revised option 2 is exercised with a new funding amount of $15,899,969. $15,899,969
Other Administrative Action P00009 · New contracting officer for this contract is jonathan gonzalez $0
Change Order P00008 $747,619
Change Order P00007 $0
Change Order P00006 $0
Change Order P00005 · The advancement of the development of a smallpox biodefense therapeutic to the clinical stage as an antibody-based countermeasure $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Exercise an Option P00002 $13,021,540
Other Administrative Action P00001 $0
Original award $9,472,446
Show all 19

About this award

Written by GovTribe AI ·

Biofactura Inc. received a $65.8 million cost-plus-fixed-fee definitive contract from the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the U.S. Department of Health and Human Services. Awarded on September 26, 2019, with an ultimate completion date of March 30, 2029, the contract encompasses preclinical and manufacturing development activities for a medical countermeasure or therapeutic agent. The scope of work includes cell line development, process development, non-clinical efficacy and safety studies, manufacturing activities, and clinical activities, with performance to occur in Frederick, Maryland. The contract was not issued under any small business set-aside designation.

The contract has been subject to a Notice of Termination for Convenience issued under the Presidential Cost Savings Initiative effective February 26, 2025. ASPR's mission includes developing, procuring, and deploying medical countermeasures and vaccines to strengthen national preparedness and response capabilities for public health emergencies. This award reflects the government's investment in advancing a potential therapeutic or vaccine candidate through critical development stages, from initial laboratory work through clinical evaluation, supporting the agency's broader biosecurity and pandemic preparedness objectives.

Description

As the agency reported it.

This contract includes preclinical and manufacturing development activities including cell line development; process development; non-clinical efficacy studies; non-clinical safety studies; manufacturing activities; clinical activities; and all as

Quick answers

Who was awarded contract 75A50119C00054?

75A50119C00054 was awarded to Biofactura Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 26, 2019.

How much is contract 75A50119C00054 worth?

The government has obligated $65,806,222 on 75A50119C00054.

Was contract 75A50119C00054 competed?

The extent of competition for 75A50119C00054 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login